ASCRS 2024: ViaLase and the FLigHT procedure

At this year's ASCRS meeting in Boston, Massachusetts, Pete England gave an update on ViaLase's development on the first femtosecond laser for the treatment of open-angle glaucoma.

Video Transcript:

Editor's note: The below transcript has been lightly edited for clarity.

Pete England:

My name is Pete England I'm with ViaLase, we are a med-tech startup developing the first femtosecond laser for the treatment of open-angle glaucoma. We're thrilled to be at ASCRS. We have two important presentations this year. And the first being Eyecelerator on Thursday, where we give an update on the technology and our regulatory approval timelines. We're also coming up [on] the news of our recent Series C fundraising closing. Which is an important milestone for the company. It's going to help us advance our key regulatory, clinical, and operational milestones to get us up to US commercialization. And then also on Sunday afternoon, we're presenting for the first time, 36-month data from our first in human study, which demonstrates the safety and IOP lowering efficacy of the FLigHT treatment, which is femtosecond laser image-guided high-precision trabeculotomy. This is a 12-month follow-up to the two-year results that were published last year, demonstrating the efficacy and safety of the FLigHT procedure. We can't wait to share more updates as we get further along our regulatory pathway at ViaLase.